MX344972B - Oligonucleotidos inmunoestimulantes. - Google Patents
Oligonucleotidos inmunoestimulantes.Info
- Publication number
- MX344972B MX344972B MX2013005544A MX2013005544A MX344972B MX 344972 B MX344972 B MX 344972B MX 2013005544 A MX2013005544 A MX 2013005544A MX 2013005544 A MX2013005544 A MX 2013005544A MX 344972 B MX344972 B MX 344972B
- Authority
- MX
- Mexico
- Prior art keywords
- immunostimulatory oligonucleotides
- compositions
- disclosed
- along
- nucleic acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones que incluyen ácidos nucleicos inmunoestimulantes, junto con el uso de dichas composiciones para inducir respuestas inmunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41419410P | 2010-11-16 | 2010-11-16 | |
PCT/US2011/061056 WO2012068295A1 (en) | 2010-11-16 | 2011-11-16 | Immunostimulatory oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005544A MX2013005544A (es) | 2013-09-26 |
MX344972B true MX344972B (es) | 2017-01-12 |
Family
ID=46084406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005544A MX344972B (es) | 2010-11-16 | 2011-11-16 | Oligonucleotidos inmunoestimulantes. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8546550B2 (es) |
EP (1) | EP2640426B1 (es) |
JP (3) | JP5933577B2 (es) |
KR (1) | KR20130116890A (es) |
CN (2) | CN103347542B (es) |
AU (2) | AU2011329850B2 (es) |
BR (1) | BR112013012195A2 (es) |
CA (1) | CA2817746A1 (es) |
DK (1) | DK2640426T3 (es) |
EA (1) | EA030096B1 (es) |
ES (1) | ES2569857T3 (es) |
IL (2) | IL226299A (es) |
MX (1) | MX344972B (es) |
WO (1) | WO2012068295A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
JP6382936B2 (ja) | 2013-03-14 | 2018-08-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ナノ粒子ベースの組成物 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN103773769B (zh) * | 2013-11-08 | 2016-09-28 | 上海交通大学 | 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途 |
RU2746406C2 (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3370694A1 (en) * | 2015-11-06 | 2018-09-12 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same |
CN108014333B (zh) * | 2017-10-11 | 2020-10-20 | 江苏省农业科学院 | 动物用粘膜靶向免疫增强剂及其在兽用疫苗中的应用 |
WO2019164872A2 (en) * | 2018-02-20 | 2019-08-29 | University Of Florida Research Foundation, Inc. | Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles |
MA52011A (fr) * | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
EP3824891A4 (en) * | 2018-07-19 | 2022-07-13 | The Research Foundation for Microbial Diseases of Osaka University | LIPID PARTICLES WITH CPG OLIGODESOXYNUCLEOTIDE TYPE A |
CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
CN114796476A (zh) * | 2021-09-24 | 2022-07-29 | 中国医学科学院医学生物学研究所 | 一种亚单位疫苗新型核酸佐剂系统及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
DK1446162T3 (da) * | 2001-08-17 | 2008-12-08 | Coley Pharm Gmbh | Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet |
WO2004058179A2 (en) * | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
CN1296378C (zh) * | 2004-05-17 | 2007-01-24 | 中国人民解放军第三军医大学 | 高免疫活性 CpG-S ODN 和拮抗 CpG-S ODN 作用的 CpG-N ODN 的基因序列及其应用 |
EP1796650B1 (en) * | 2004-09-14 | 2009-01-07 | NanoDel Technologies GmbH | Delivery vehicle containing nanoparticles |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
CA2653939C (en) * | 2006-05-31 | 2013-01-22 | Toray Industries, Inc. | Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
MX2009010907A (es) * | 2007-04-13 | 2010-03-17 | Univ North Texas | Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer. |
BRPI0817664A2 (pt) * | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
CN102686244A (zh) * | 2009-04-21 | 2012-09-19 | 西莱克塔生物科技公司 | 提供一种Th1-偏向性应答的免疫纳米疗法 |
KR101873179B1 (ko) * | 2009-08-26 | 2018-06-29 | 셀렉타 바이오사이언시즈, 인크. | T-세포 도움을 유도하는 조성물 |
-
2011
- 2011-11-16 JP JP2013539986A patent/JP5933577B2/ja not_active Expired - Fee Related
- 2011-11-16 EP EP11841555.3A patent/EP2640426B1/en not_active Not-in-force
- 2011-11-16 CN CN201180065158.1A patent/CN103347542B/zh not_active Expired - Fee Related
- 2011-11-16 WO PCT/US2011/061056 patent/WO2012068295A1/en active Application Filing
- 2011-11-16 KR KR1020137015349A patent/KR20130116890A/ko not_active Application Discontinuation
- 2011-11-16 EA EA201300585A patent/EA030096B1/ru not_active IP Right Cessation
- 2011-11-16 US US13/298,173 patent/US8546550B2/en not_active Expired - Fee Related
- 2011-11-16 DK DK11841555.3T patent/DK2640426T3/en active
- 2011-11-16 MX MX2013005544A patent/MX344972B/es active IP Right Grant
- 2011-11-16 BR BR112013012195A patent/BR112013012195A2/pt not_active Application Discontinuation
- 2011-11-16 AU AU2011329850A patent/AU2011329850B2/en not_active Ceased
- 2011-11-16 ES ES11841555.3T patent/ES2569857T3/es active Active
- 2011-11-16 CA CA2817746A patent/CA2817746A1/en not_active Abandoned
- 2011-11-16 CN CN201510502657.2A patent/CN105327363A/zh active Pending
-
2013
- 2013-05-12 IL IL226299A patent/IL226299A/en active IP Right Grant
-
2016
- 2016-05-02 JP JP2016092527A patent/JP6203897B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-01 IL IL252061A patent/IL252061A0/en not_active IP Right Cessation
- 2017-06-01 AU AU2017203714A patent/AU2017203714A1/en not_active Abandoned
- 2017-08-30 JP JP2017165155A patent/JP2018023389A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018023389A (ja) | 2018-02-15 |
EA030096B1 (ru) | 2018-06-29 |
EA201300585A1 (ru) | 2013-11-29 |
JP5933577B2 (ja) | 2016-06-15 |
CN103347542B (zh) | 2015-09-16 |
IL226299A (en) | 2017-05-29 |
AU2017203714A1 (en) | 2017-06-22 |
DK2640426T3 (en) | 2016-05-02 |
EP2640426A4 (en) | 2014-11-05 |
IL226299A0 (en) | 2013-07-31 |
JP2016189777A (ja) | 2016-11-10 |
IL252061A0 (en) | 2017-07-31 |
MX2013005544A (es) | 2013-09-26 |
AU2011329850B2 (en) | 2017-03-02 |
US8546550B2 (en) | 2013-10-01 |
BR112013012195A2 (pt) | 2018-07-10 |
EP2640426A1 (en) | 2013-09-25 |
ES2569857T3 (es) | 2016-05-12 |
US20120213812A1 (en) | 2012-08-23 |
KR20130116890A (ko) | 2013-10-24 |
EP2640426B1 (en) | 2016-02-03 |
JP2014501504A (ja) | 2014-01-23 |
WO2012068295A1 (en) | 2012-05-24 |
CN105327363A (zh) | 2016-02-17 |
JP6203897B2 (ja) | 2017-09-27 |
CN103347542A (zh) | 2013-10-09 |
AU2011329850A1 (en) | 2013-06-06 |
CA2817746A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
IL273838A (en) | Peptide and oligonucleotide conjugates, preparations containing them and their uses | |
EP3698631A3 (en) | Methods of delivering oligonucleotides to immune cells | |
WO2015085318A3 (en) | Targeted adaptive vaccines | |
MX2018016021A (es) | Composiciones y metodos que comprenden variante de enzima lipolitica. | |
WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
MX354267B (es) | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. | |
MX371497B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica. | |
IL247469B (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
MX371018B (es) | Polipéptidos que tienen actividad de transgalactosilación. | |
WO2014096992A8 (en) | Acetyl transferases and their use for producing carotenoids | |
MX349630B (es) | Alfa-amilasas. | |
EA201291157A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
GB201218752D0 (en) | Mineral complex, compositions thereof, and methods of using the same | |
GB2537077A (en) | Methods for sequencing nucleic acids | |
IN2014DN09085A (es) | ||
ZA201404199B (en) | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same. | |
JO3755B1 (ar) | تركيبات تستوستيرون | |
WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
MX369662B (es) | Granulos de harina de microalgas y proceso de preparacion de estos. | |
HK1219426A1 (zh) | 包含免疫刺激性寡核苷酸的新穎疫苗組合物 | |
MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
EP2861738A4 (en) | METHODS AND COMPOSITIONS ASSOCIATED WITH THE SMCHD1 GENE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |